Postpartum hemorrhage: Blood product management and massive transfusion

Benjamin K Kogutt; Arthur J Vaught

doi:10.1053/j.semperi.2018.11.008

Postpartum hemorrhage: Blood product management and massive transfusion

Semin Perinatol. 2019 Feb;43(1):44-50. doi: 10.1053/j.semperi.2018.11.008. Epub 2018 Nov 14.

Authors

Benjamin K Kogutt¹, Arthur J Vaught²

Affiliations

¹ Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine, Johns Hopkins Hospital, Johns Hopkins University Medical Center, Baltimore, MD, United States. Electronic address: [email protected].
² Department of Gynecology and Obstetrics, Division of Maternal Fetal Medicine, Johns Hopkins Hospital, Johns Hopkins University Medical Center, Baltimore, MD, United States; Department of Surgery, Division of Surgical Critical Care, Johns Hopkins Hospital, Johns Hopkins University Medical Center, Baltimore, MD, United States.

Abstract

Blood product transfusion capabilities are crucial for appropriate response to postpartum hemorrhage. Novel treatments are continually being sought to improve maternal morbidity and mortality associated with massive hemorrhage.

Keywords: Adjuncts; Hemorrhage; Massive Transfusion.

Publication types

Review

MeSH terms

Antifibrinolytic Agents / therapeutic use*
Blood Transfusion* / methods
Clinical Protocols
Delivery, Obstetric
Female
Humans
Postpartum Hemorrhage / therapy*
Pregnancy
Tranexamic Acid / therapeutic use*

Substances

Antifibrinolytic Agents
Tranexamic Acid

Grants and funding

K12 HD085845/HD/NICHD NIH HHS/United States